OR WAIT null SECS
© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
A panel of experts review data from recent conferences and discuss core challenges in the treatment of patients with HER2+ metastatic breast cancer.
November 16th 2021
Panelists provide an overview of the treatment landscape for patients with HER2-positive metastatic breast cancer.
A panel of experts reviews clinical trial data in recurrent HER2-positive metastatic breast cancer and discusses impacts on treatment selection.
November 23rd 2021
Fielding questions from a live audience, experts discuss the lack of biomarkers in HER2+ metastatic breast cancer and how one might address progression of bone disease.
Using a patient case to center their discussion, the panel reviews frontline treatment options for HER2+ metastatic breast cancer and the rationale behind selection.